Posted by Michael Wonder on 14 May 2019
Cellectar receives FDA fast track designation for CLR 131 in relapsed or refractory multiple myeloma
13 May 2019 - Designation could accelerate CLR 131 development and underscores the need for new treatments.
Cellectar Biosciences today announced that the U.S. FDA has granted fast track designation for CLR 131 in fourth line or later relapse/refractory multiple myeloma. CLR 131 is the company’s small-molecule radiotherapeutic phospholipid drug conjugate designed to deliver cytotoxic radiation directly and selectively to cancer cells and cancer stem cells.
It is currently being evaluated in Cellectar’s ongoing CLOVER-1 Phase 2 clinical study in patients with relapsed or refractory multiple myeloma and other select B-Cell lymphomas.
